Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Fibroblast growth factor receptors as treatment targets in clinical oncology
Masaru Katoh
Nature Reviews Clinical Oncology (2018) Vol. 16, Iss. 2, pp. 105-122
Closed Access | Times Cited: 299

Showing 1-25 of 299 citing articles:

FGF/FGFR signaling in health and disease
Yangli Xie, Nan Su, Jing Yang, et al.
Signal Transduction and Targeted Therapy (2020) Vol. 5, Iss. 1
Open Access | Times Cited: 588
Targeting the HIF2–VEGF axis in renal cell carcinoma
Toni K. Choueiri, William G. Kaelin
Nature Medicine (2020) Vol. 26, Iss. 10, pp. 1519-1530
Closed Access | Times Cited: 356
The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy
Jimin Yuan, Xiaoduo Dong, Jiajun Yap, et al.
Journal of Hematology & Oncology (2020) Vol. 13, Iss. 1
Open Access | Times Cited: 353
Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer
Feng Ye, Saikat Dewanjee, Yuehua Li, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 259
Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance
Melanie A. Krook, Julie W. Reeser, Gabrielle Ernst, et al.
British Journal of Cancer (2020) Vol. 124, Iss. 5, pp. 880-892
Open Access | Times Cited: 250
Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors HarboringFGF/FGFRAberrations: A Phase I Dose-Expansion Study
Funda Meric‐Bernstam, Rastislav Bahleda, Cinta Hierro, et al.
Cancer Discovery (2021) Vol. 12, Iss. 2, pp. 402-415
Open Access | Times Cited: 198
Precision medicine for human cancers with Notch signaling dysregulation (Review)
Masuko Katoh, Masaru Katoh
International Journal of Molecular Medicine (2019)
Open Access | Times Cited: 169
PROTACs: great opportunities for academia and industry (an update from 2020 to 2021)
Ming He, Chao-Guo Cao, Zhihao Ni, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 165
Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study
Zev A. Wainberg, Peter C. Enzinger, Yoon‐Koo Kang, et al.
The Lancet Oncology (2022) Vol. 23, Iss. 11, pp. 1430-1440
Closed Access | Times Cited: 144
The Role of Fibroblast Growth Factor (FGF) Signaling in Tissue Repair and Regeneration
Mariya Farooq, Abdul Waheed Khan, Moon Suk Kim, et al.
Cells (2021) Vol. 10, Iss. 11, pp. 3242-3242
Open Access | Times Cited: 143
Receptor tyrosine kinases and cancer: oncogenic mechanisms and therapeutic approaches
Punit Saraon, Shivanthy Pathmanathan, Jamie Snider, et al.
Oncogene (2021) Vol. 40, Iss. 24, pp. 4079-4093
Closed Access | Times Cited: 133
Signaling pathways in cancer‐associated fibroblasts: recent advances and future perspectives
Zengli Fang, Qingcai Meng, Jin Xu, et al.
Cancer Communications (2022) Vol. 43, Iss. 1, pp. 3-41
Open Access | Times Cited: 132
Inhibition of FGF‐FGFR and VEGF‐VEGFR signalling in cancer treatment
Guihong Liu, Tao Chen, Zhenyu Ding, et al.
Cell Proliferation (2021) Vol. 54, Iss. 4
Open Access | Times Cited: 130
FGFR-TKI resistance in cancer: current status and perspectives
Sitong Yue, Yukun Li, Xiaojuan Chen, et al.
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 113
Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study
Shubham Pant, Martin Schüler, Gopa Iyer, et al.
The Lancet Oncology (2023) Vol. 24, Iss. 8, pp. 925-935
Closed Access | Times Cited: 94
Signaling pathways and targeted therapies in lung squamous cell carcinoma: mechanisms and clinical trials
Zhenyi Niu, Runsen Jin, Yan Zhang, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 91
Small molecule inhibitors targeting the cancers
Guihong Liu, Tao Chen, Xin Zhang, et al.
MedComm (2022) Vol. 3, Iss. 4
Open Access | Times Cited: 87
RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity acrossFGFR2Alterations and Resistance Mutations
Vivek Subbiah, Vaibhav Sahai, Dejan Maglic, et al.
Cancer Discovery (2023) Vol. 13, Iss. 9, pp. 2012-2031
Open Access | Times Cited: 65
Structural basis for FGF hormone signalling
Lingfeng Chen, Lili Fu, Jingchuan Sun, et al.
Nature (2023) Vol. 618, Iss. 7966, pp. 862-870
Open Access | Times Cited: 59
FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions
Masuko Katoh, Yohann Loriot, Giovanni Brandi, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 4, pp. 312-329
Closed Access | Times Cited: 57
Unleashing the potential of combining FGFR inhibitor and immune checkpoint blockade for FGF/FGFR signaling in tumor microenvironment
Ruiwen Ruan, Li Li, Xuan Li, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 50
Therapeutic advances of targeting receptor tyrosine kinases in cancer
Ciprian Tomuleasa, Adrian Bogdan Țigu, Raluca Munteanu, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 23
Discovery of lirafugratinib (RLY-4008), a highly selective irreversible small-molecule inhibitor of FGFR2
Heike Schönherr, Pelin Ayaz, Alexander M. Taylor, et al.
Proceedings of the National Academy of Sciences (2024) Vol. 121, Iss. 6
Open Access | Times Cited: 22
The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder
Robert Roskoski
Pharmacological Research (2019) Vol. 151, pp. 104567-104567
Closed Access | Times Cited: 114
Facts and New Hopes on Selective FGFR Inhibitors in Solid Tumors
Francesco Facchinetti, Antoine Hollebecque, Rastislav Bahleda, et al.
Clinical Cancer Research (2019) Vol. 26, Iss. 4, pp. 764-774
Open Access | Times Cited: 105
Page 1 - Next Page

Scroll to top